Literature DB >> 29602129

Sanyang Xuedai enhances the radiosensitivity of human non-small cell lung cancer cells via increasing iNOS/NO production.

Li Wang1, Yaoxiong Xia1, Ting Chen2, Yueqin Zeng3, Lan Li1, Yu Hou1, Wenhui Li4, Zhijie Liu5.   

Abstract

OBJECTIVE: In this research, we aimed at finding out how San Yang Xue Dai (SYKT) promotes the radiosensitivity of non-small cell lung cancer (NSCLC) cell line NCI-H460.
METHODS: Survival rate of NSCLC cells (A549, NCI-H460, NCI-H1650 and NCI-H1975) after the SYKT treatment or irradiation (IR) was calculated by the MTT assay. The radiosensitization of SYKT (0.5 g/mL and 1.0 g/mL) on cell line NCI-H460 and the radioresistant cell line NCI-H460R was studied by MTT assay and clone formation assay. The protein expression levels of iNOS, Cyclin B1 and CDC2 were determined by western blot, and the expression of NO was measured by Griess method. Finally, cell cycle and apoptotic rate of NSCLC cell line NCI-H460 were accessed by flow cytometry assay. BrdU staining was also applied to detect the cell proliferation after IR with or without SYKT treatment.
RESULTS: The IC10 value of SYKT for NCI-H460 cells was 1.03 g/mL. After 1.0 g/mL SYKT treatment, the radiosensitivity of NCI-H460R cells was enhanced. The level of iNOS in the cells was found decreased after IR. We also found that SYKT could enhance iNOS and NO expressions while inhibit cyclin B1 and CDC2 expressions in radiation resistant cells. Combining β-irradiation with SYKT caused cell cycle arrest in G2/M phase and increased cell apoptosis.
CONCLUSION: SYKT resensitized radioresistant NCI-H460R cells via increasing cell apoptosis and cell cycle arrest. This was due to an elevated NO level caused by accumulating iNOS and effects of SYKT on radiosensitization of NSCLC should be further investigated in clinical application.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; Radiosensitivity; Sanyang Xuedai (SYKT); iNOS/NO

Mesh:

Substances:

Year:  2018        PMID: 29602129     DOI: 10.1016/j.biopha.2018.03.017

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

1.  VPS33B modulates c-Myc/p53/miR-192-3p to target CCNB1 suppressing the growth of non-small cell lung cancer.

Authors:  Jiahao Liu; Yinghao Wen; Zhen Liu; Shu Liu; Ping Xu; Yan Xu; Shuting Deng; Shulu Hu; Rongcheng Luo; Jingwen Jiang; Guifang Yu
Journal:  Mol Ther Nucleic Acids       Date:  2020-11-17       Impact factor: 8.886

2.  Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer.

Authors:  Xiaobin Gu; Yonggang Shi; Meilian Dong; Li Jiang; Jing Yang; Zheyan Liu
Journal:  Cell Death Dis       Date:  2021-08-30       Impact factor: 8.469

3.  SYKT Alleviates Doxorubicin-Induced Cardiotoxicity via Modulating ROS-Mediated p53 and MAPK Signal Pathways.

Authors:  Ting Chen; Zhiyong Deng; Ruilian Zhao; Hongmei Shen; Wenhui Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-26       Impact factor: 2.629

4.  Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.

Authors:  Gang Chen; Mingwei Yu; Jianqiao Cao; Huishan Zhao; Yuanping Dai; Yizi Cong; Guangdong Qiao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.